

# **EXPERT PERSPECTIVES**

## **ON CHRONIC LIVER DISEASE**

### **FROM ACG & AASLD**

#### **Program Overview:**

This educational initiative will provide healthcare professionals (HCPs) with the most current insights on a range of chronic liver diseases. This series will consist of accredited livestream meetings designed to review and discuss the latest research and clinical data presented at these congresses. The series will be complemented by accessible archived livestreams and supplementary educational resources on CLDF and GHAPP educational portals.

#### **Target Audience:**

HCPs, including gastroenterologists, hepatologists, nurse practitioners, physician associates, and nurses, specializing in the treatment of CLD.

#### **Planning Committee/Faculty:**

Gideon Hirshfield, FRCP, PhD  
Robert Wong, MD, MS, FACP, FAASLD  
Elizabeth Goacher, PA-C  
Lisa Pedicone, Ph-D

#### **Educational Objectives:**

- Identify the diagnostic criteria for MASLD/MASH, PBC, HCC, and complications of cirrhosis, using non-invasive tests (NITs) and biomarkers.
- Understand the emerging pharmacologic treatments for these diseases, including GLP-1 receptor agonists, targeted therapies, and immunomodulatory agents, and their clinical applications.
- Incorporate weight management and lifestyle modifications into the treatment strategy to improve liver health and reduce disease progression.
- Use the latest clinical trial data on these diseases to inform clinical decision-making and improve patient outcomes.

#### **Accreditation Statement:**

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati, the Chronic Liver Disease Foundation, and Gastroenterology and Hepatology Advanced Practice Providers. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

The University of Cincinnati designates this live activity for a maximum of **1.0 AMA PRA Category 1 Credit™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

#### **Disclosure of Relevant Financial Relationships:**

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education and the University of Cincinnati policy, all faculty, planning committee members, and other individuals, who are in a position to control content, are required to disclose all relationships with ineligible companies\* (commercial interests) within the last 24 months. All educational materials are reviewed for fair balance, scientific objectivity, and levels of evidence. The ACCME requires us to disqualify from involvement in the planning and implementation of accredited continuing education any individuals (1) who refuse to provide this information or (2) whose conflicts of interests cannot be mitigated.

\*Companies that are ineligible to be accredited in the ACCME System (ineligible companies) are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant relationships have been mitigated prior to the commencement of this activity.

All additional planning committee members, the University of Cincinnati staff, the Chronic Liver Disease Foundation, and Gastroenterology and Hepatology Advanced Practice Provider staff have no relationships to disclose.

## **Planning Committee and Faculty Disclosures:**

- **Gideon Herschfield, FRCP, PhD**
  - Consultant: Intercept, Ipsen, GSK, Gilead, Kowa, Pliant, Chemomab, Amgen, Mirum, Kezar
- **Robert Wong, MD, MS, FACP, FAASLD**
  - Research Grant: Gilead Sciences, Exact Sciences, Madrigal Pharmaceuticals
- **Elizabeth Goacher, PA-C**
  - Consultant: GSK, Gilead, Ipsen, Madrigal Pharmaceuticals
- **Lisa Pedicone, PhD – medical writer**
  - No relevant financial relationships to disclose.

## **Disclaimer:**

The opinions expressed during the educational activity are those of the faculty and do not necessarily represent the views of the University of Cincinnati. The information is presented for the purpose of advancing the attendees' professional development.

## **Off-Label Disclosure Statement:**

Faculty members are required to inform the audience when they are discussing off-label, unapproved uses of devices and drugs. Physicians should consult full prescribing information before using any product mentioned during this educational activity.

**Fee information:** No Fees

Jointly provided by the University of Cincinnati, the Chronic Liver Disease Foundation,  
and Gastroenterology and Hepatology Advanced Practice Providers.



Supported by educational grants from Gilead Sciences, Inc., Ipsen Biopharmaceuticals, Inc., and Salix Pharmaceuticals.